Treatment for Kanakadi (Urticaria) by using Gandhaga rasayanam and Arugan thylam

Phase 3

Completed

• Conditions: Urticaria, unspecified,

• Registration Number: CTRI/2022/11/047671
• Lead Sponsor: National Institute of Siddha

Brief Summary

The aim to evaluate the effective of Gandhaga Rasayanam(internal) and Arugan thylam(external) in the management of kaanaakadi (urticaria).To assess the therapeutic efficacy of Siddha formulation Gandhaga Rasayanam and Arugan thylam in the management of kaanaakadi. This trial drug will be issued to the patient .The patient will be asked to visit OPD of Ayothidoss pandithar hospital National institute of Siddha with 40 patients once 10 days for clinical assessment.  Patient selected based on inclusion and exclusion criteria. Laboratory investigation taken before and after treatment. All the data entered into computer and analysed. All collected data will be statistically analysed by Research officer (statistics) for logical errors and incompleteness of data to avoid any bias.Then final report will be generated.The outcome will be assessed by based on Urticaria Activity Score and IgE before and after treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-25
• Last Update Posted: 2023-09-23
• Study Completion: 2023-10-05

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with clinical symptoms of Itching Redness Pale pink oedematous wheal Wheals surrounded by flare Inflamation Erythematous macules (any 2 symptoms especially itchy,wheal) Recurrent episodes of urticaria.

Exclusion Criteria

Any serious systemic illness Psoriasis Eczema Tinea infection Pregnancy Lactation Psychological factor Adverse reaction of any drug.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effect of Gandhaga rasayanam(internal) and arugan thylam(external) in the management of urticaria will be assessed by based on urticaria activity score(UAS) and IgE in study subjects before and after the treatment.	48 Days

Trial Locations

Locations (1)

National Institute of Siddha; 🇮🇳 Chennai, TAMIL NADU, India

National Institute of Siddha

🇮🇳Chennai, TAMIL NADU, India

S MANJU

Principal investigator

09498073226

manjukrishnaveni04@gmail.com